Citi lowered the firm’s price target on Penumbra (PEN) to $285 from $320 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra announces FDA approval, launch of Ruby XL System
- Penumbra: Strong Market Position and Growth Potential Drive Buy Rating
- Penumbra Amends Incorporation Certificate After Stockholder Vote
- Penumbra’s Growth Potential Boosted by STORM-PE Trial and Thunderbolt Device Innovations
- Penumbra’s Strategic Positioning and Growth Potential Justify Buy Rating